Advances in biologic therapy for ulcerative colitis and Crohn's disease

Current Gastroenterology Reports

Volumn 8, Issue 6, 2006, Pages 506-512

  D'Haens, Geert ^a   Daperno, Marco ^b  

^a IMELDA HOSPITAL   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABT 874; ADALIMUMAB; ALICAFORSEN; AMINOSALICYLIC ACID DERIVATIVE; ATLIZUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; ETANERCEPT; FONTOLIZUMAB; GAMMA INTERFERON ANTIBODY; HUMAN GROWTH HORMONE; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 6 ANTIBODY; MESALAZINE; MLN 02; NATALIZUMAB; ONERCEPT; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TUMOR NECROSIS FACTOR ANTIBODY; VISILIZUMAB;

ANTIINFLAMMATORY ACTIVITY; ASTHENIA; BACTERIAL PNEUMONIA; BONE PAIN; CHILL; CLINICAL TRIAL; COLON RESECTION; CROHN DISEASE; CYTOKINE RELEASE; DISEASE SEVERITY; DOSE RESPONSE; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; FLU LIKE SYNDROME; HEADACHE; HUMAN; IMMUNOGENICITY; INFLUENZA; INJECTION SITE REACTION; LIVER DYSFUNCTION; MAINTENANCE THERAPY; NAUSEA AND VOMITING; OPTIMAL DRUG DOSE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REMISSION; REVIEW; SIDE EFFECT; TUBERCULOSIS; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TREATMENT OUTCOME;

EID: 33845896308     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-006-0041-5     Document Type: Review

References (43)

1. Järnerot G, Hertervig E, Friis-Liby I, et al.: Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005, 128:1805-1811.
2. Rutgeerts P, Sandborn WJ, Feagan BG, et al.: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476.
3. D'Haens G: Infliximab for ulcerative colitis: finally some answers [editorial]. Gastroenterology 2005, 128:2161-2164.
4. Feagan BG, Greenberg GR, Wild G, et al.: Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005, 352:2499-2507.
5. van Deventer SJH, Tami JA, Wedel MK, et al.: A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut 2004, 53:1646-1651.
6. Miner PBJ, Wedel MK, Xia S, et al.: Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double blind, active-controlled trial. Aliment Pharmacol Ther 2006, 23:1403-1413.
7. van Deventer SJ, Wedel MK, Baker BF, et al.: A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Aliment Pharmacol Ther 2006, 23:1415-1425.
8. Targan S, Salzberg B, Mayer L, et al.: A Phase 1 study: multiple dose levels of visilizumab are well tolerated and produce rapid and sustained improvement in ulcerative colitis patients refractory to treatment with intravenous steroids. Gastroenterology 2005, 128:A75.
9. Van Assche G, Sandborn WJ, Feagan BG, et al.: Daclizumab, a humanized monoclonal antibody to the interleukin-2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double-blind, placebo-controlled, dose-ranging trial. Gut 2006, April 7; [Epub ahead of print].
10. Sandborn WJ, Hanauer SB, Katz S, et al.: Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001, 121:1088-1094.
11. Rutgeerts P, Lemmens L, Van Assche G, et al.: Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. Aliment Pharmacol Ther 2003, 17:185-192.
12. Hanauer SB, Feagan BG, Lichtenstein GR, et al.: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
13. Sands BE, Anderson FH, Bernstein CN, et al.: Infliximab maintenance therapy for fistulizing Crohn's disease N Engl J Med 2004, 350:876-885.
14. Lichtenstein GR, Feagan BG, Cohen RD, et al.: Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006, 4:621-630.
15. Bongartz T, Sutton AJ, Sweeting MJ, et al.: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295:2275-2285.
16. Van Assche G, Paintaud G, D'Haens G, et al.: Continuation of immunosuppression is not required to maintain adequate infliximab efficacy in patients with Crohn's disease bur may improve pharmacokinetics. Gastroenterology 2006, 130:A-142.
17. Hommes D, Baert F, Van Assche G, et al.: The ideal management of Crohn's disease: top down versus step up strategies, a randomized controlled trial [abstract 749]. Gastroenterology 2006, 130:A108.
18. D'Haens G, Hommes D, Baert F, et al.: A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn's disease [abstract 7641]. Gastroenterology 2006, 130:A110.
19. Beaugerie L, Seksik P, Nion-Larmurier I, et al.: Predictors of Crohn's disease. Gastroenterology 2006, 130:650-656.
20. Hanauer SB, Sandborn WJ, Rutgeerts P, et al.: Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006, 130:323-333.
21. Colombel JF, Sandborn W, Rutgeerts P, et al.: Adalimumab induces and maintains clinical response and remission in patients with active crohn's disease: results of the CHARM Trial [late breaking abstract]. Dig Dis Week 2006. Available online at http://www.ddw.org/.
22. Sandborn WJ, Hanauer S, Loftus EVJ, et al.: An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 2004, 99:1984-1989.
23. Papadakis KA, Shaye OA, Vasiliauskas EA, et al.: Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol 2005, 100:75-79.
24. Schreiber S, Rutgeerts P, Fedorak RN, et al.: A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005, 129:807-818.
25. Schreiber S, Khaliq-Kareemi M, Lawrance I, et al.: Certolizumab pegol, a humanized anti-TNF pegylated Fab' fragment, is safe and effective in the maintenance of response and remission following induction in active Crohn's disease: a phase III study (Precise). Gut 2005, 37:A82.
26. Sandborn W, Feagan B, Stoinov S, et al.: Certolizuman pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26-weck, placebo-controlled phase III study (Precise 1). Gastroenterology 2006, 130:A107.
27. Mannon PJ, Fuss IJ, Mayer L, et al.: Anti-interleukin-12 antibody for active crohn's disease. N Engl J Med 2004, 351:2069-2079.
28. Reinisch W, Hommes DW, Van Assche G, et al.: A dose-escalating, placebo-controlled, double-blind, single-dose and multi-dose, safety and tolerability study of fontolizumab, a humanised anti-interferon- gamma antibody, in patients with moderate-to-severe Crohn's disease. Gut 2006, 55:1138-1144.
29. Hommes DW, Mikhajlova TL, Stoinov S, et al.: Fontolizumab, a humanised anti-interferon-gamma antibody, demonstrates safety and potential clinical activity in patients with moderate-to-severe Crohn's disease. Gut 2006, 55:101-1137.
30. Ito H, Takazoe M, Fukuda Y, et al.: A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004, 126:989-996.
31. Hommes D, Targan S, Baumgart DC, et al.: A phase I study: visilizumab therapy in Crohn's disease (CD) patients refractory to infliximab treatment [abstract 769]. Gastroenterology 2006, 130:A111.
32. Sandborn WJ, Colombel JF, Enns R, et al.: Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005, 353:1912-1925.
33. Targan SR, Feagan B, Fedorak R, et al.: Natalizumab induces sustained response and remission in patients with active Crohn's disease: results from the ENCORE trial. Gastroenterology 2006, 130:A108.
34. Van Assche G, Van Ranst M, Sciot R, et al.: Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005, 353:362-368.
35. Langer-Gould A, Atlas SW, Green AJ, et al.: Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005, 353:375-381.
36. Kleinschmidt-DeMasters BK, Tyler KL: Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005, 353:369-374.
37. Sandborn WJ, Targan S: A safety evaluation for progressive multifocal leukoencephalopathy (PML) in greater than 3,500 patients with Crohn's disease (CD), multiple sclerosis (MS), and rheumatoid arthritis (RA) previously treated with natalizumab in clinical trials [abstract 492]. Gastroenterology 2006, 130:A72.
38. Yousry TA, et al.: Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006, 354:924-933.
39. Vespasiani Gentilucci U, Caviglia R, Picardi A, et al.: Infliximab reverses growth hormone resistance associated with inflammatory bowel disease. Aliment Pharmacol Ther 2005, 21:1063-1071.
40. Slonim AE, Bulone L, Damore MB, et al.: A preliminary study of growth hormone therapy for Crohn's disease. N Engl J Med 2000, 342:1633-1637.
41. Korzenik J, Dieckgraefe B: Immunostimulation in Crohn's disease: results of a pilot study of G-CSF in mucosal and fistulizing Crohn's disease. Gastroenterology 2000, 118:A874.
42. Korzenik J, Pittler A, Dieckgraefe B: Immunostimulation in Crohn's disease: retreatment and maintenance therapy with GM-CSF. Gastroenterology 2002, 122:A432.
43. Korzenik JR, Dieckgraefe BK, Valentine JF, et al.: Sargramostim for active Crohn's disease. N Engl J Med 2005, 352:2193-2201.